Queen's University at Kingston
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1841-10-16
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.queensu.ca
Clinical Trials
312
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (287 trials with phase data)• Click on a phase to view related trials
Bone Enhanced Ultrasound (BEUS) Data Library Development Project
- Conditions
- Lower Back PainFacet Joint Pain; Low Back PainOsteoarthritis (OA)
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 100
- Registration Number
- NCT07036653
Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery
- Conditions
- Pelvic Organ Prolapse (POP)
- Interventions
- Drug: Vaginal Estrogen - Twice WeeklyDrug: Vaginal Estrogen - Daily
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 180
- Registration Number
- NCT07030426
- Locations
- 🇨🇦
Health Sciences Centre, St John's, Newfoundland and Labrador, Canada
🇨🇦Kingston Health Sciences Centre, Kingston, Ontario, Canada
Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD
- Conditions
- Chronic PainPosttraumatic Stress Disorder (PTSD)
- Interventions
- Behavioral: Mindfulness-based cognitive therapy
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 30
- Registration Number
- NCT07009158
Does a Virtual Program for Pelvic Pain Improve Pain and Sexual Outcomes in Individuals With Provoked Vestibulodynia?
- Conditions
- Vulvodynia (Chronic Vulvar Pain)Vulvar VestibulitisVestibulodyniaProvoked VestibulodyniaProvoked Localized Vulvodynia
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 250
- Registration Number
- NCT06999395
Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
- Conditions
- Generalized Anxiety Disorder (GAD)
- Interventions
- Other: Placebo
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 50
- Registration Number
- NCT06969170
- Locations
- 🇨🇦
Kingston General Health Research Institute, Kingston, Ontario, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 62
- Next
News
World-First Clinical Trial Demonstrates Exercise Significantly Improves Colon Cancer Survival
A groundbreaking 17-year international clinical trial involving 889 colon cancer patients shows that structured exercise programs reduce cancer recurrence risk by 28% and death risk by 37%.
myeloMATCH Trials Open to Accelerate Precision Medicine for AML and MDS
myeloMATCH, a collaborative effort by leading cancer research organizations, launches clinical trials to advance precision medicine for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Stepped Care Model Shows Promise in Enhancing Adherence to Internet-Based CBT for Depression
A recent study investigated the efficacy of a stepped care model combined with internet-based cognitive behavioral therapy (i-CBT) for adults with major depressive disorder (MDD).